Guardant Health (NASDAQ:GH) Given New $145.00 Price Target at BTIG Research

Guardant Health (NASDAQ:GH) had its price objective hoisted by BTIG Research from $140.00 to $145.00 in a report released on Friday, Marketbeat.com reports. The firm currently has a buy rating on the stock.

Several other analysts also recently weighed in on GH. Canaccord Genuity Group upped their price target on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus boosted their target price on Guardant Health from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Robert W. Baird began coverage on Guardant Health in a report on Tuesday. They set an “outperform” rating and a $120.00 price target for the company. JPMorgan Chase & Co. lifted their price target on Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, UBS Group reiterated a “buy” rating and issued a $175.00 price target on shares of Guardant Health in a research note on Friday, January 30th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.43.

Guardant Health Price Performance

NASDAQ:GH opened at $103.10 on Friday. The firm’s 50-day moving average price is $106.69 and its 200-day moving average price is $85.94. The company has a market capitalization of $12.99 billion, a PE ratio of -31.15 and a beta of 1.63. Guardant Health has a 1-year low of $34.88 and a 1-year high of $120.74.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. Guardant Health’s revenue for the quarter was up 39.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.62) earnings per share. Equities analysts anticipate that Guardant Health will post -2.9 EPS for the current fiscal year.

Insider Buying and Selling

In other Guardant Health news, insider Terilyn J. Monroe sold 8,571 shares of the business’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $114.09, for a total value of $977,865.39. Following the completion of the transaction, the insider owned 20,990 shares of the company’s stock, valued at approximately $2,394,749.10. The trade was a 28.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Amirali Talasaz sold 100,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the transaction, the chief executive officer owned 168,223 shares in the company, valued at $17,671,826.15. This represents a 37.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 434,511 shares of company stock worth $45,580,887 in the last three months. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Guardant Health

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Guardant Health by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after buying an additional 251,939 shares during the period. Price T Rowe Associates Inc. MD increased its position in Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in Guardant Health by 6.6% in the third quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock valued at $320,378,000 after acquiring an additional 317,906 shares during the period. Invesco Ltd. boosted its position in Guardant Health by 27.3% in the second quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after purchasing an additional 763,834 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in Guardant Health by 14.9% in the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after purchasing an additional 435,232 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health News Summary

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.